Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315276 · ClinicalTrials.gov registry record · Phase 2
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
A Phase 2 study of Attention Deficit Hyperactivity Disorder and ADHD, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
- 370
- Enrollment target
- 18
- Study locations
NCT00315276 is a Phase 2 study of Attention Deficit Hyperactivity Disorder and ADHD that has completed, run by Cephalon. The registered enrollment target is 370 participants, above the 203-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (82% higher). The trial reports 18 study locations across 15 states.
The verdict
NCT00315276, a Phase 2 study of Attention Deficit Hyperactivity Disorder and ADHD, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 370 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy and safety of modafinil administered once daily for 9 weeks at doses of 255, 340, 425, and 510 mg as treatment for adults with ADHD.
Conditions Studied
Interventions
- DRUG Modafinil
Study Locations (18)
California
- Bay Area Research Institute - Lafayette
- Pharmacology Research Institute - Northridge
- Peninsula Research Associates - Rolling Hills Estates
- UCSD Medical Center - San Diego
Arkansas
- Neurology Clinical Study Centers, LLC - Little Rock
Florida
- Clinical Neuroscience Solution, Inc. - Orlando
Illinois
- University of Illinois - Chicago
Kentucky
- Michael J. Reiser, MD, LLC - Lexington
Maryland
- Adult ADD Center of Maryland - Lutherville
Massachusetts
- Massachusetts General Hospital - Cambridge
Michigan
- Rochester Center for Behavioral Medicine - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315276
The ClinicalTrials.gov registry entry for NCT00315276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (82% higher). The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Modafinil is the first listed.
NCT00315276 reports 18 study locations spanning 15 distinct geographic areas - top geographies include California, Arkansas, Florida.
Frequently Asked Questions
What is clinical trial NCT00315276 about?
NCT00315276 is a clinical study titled "Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD". The purpose of the study is to evaluate the efficacy and safety of modafinil administered once daily for 9 weeks at doses of 255, 340, 425, and 510 mg as treatment for adults with ADHD.
What is the current status of trial NCT00315276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 370 participants. The study started on 2006-05. Estimated completion is 2007-01.
What conditions does trial NCT00315276 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, ADHD.
What interventions are being tested in trial NCT00315276?
The interventions under investigation include: Modafinil (DRUG).
Who is sponsoring clinical trial NCT00315276?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315276 being conducted?
This trial has 18 study locations across Arkansas, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
COMPLETED · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
COMPLETED · Phase 2
-
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.